Review: P. S. FRIEDMANN, B. B. TAN, E. MUSABA & I. STRICKLAND
1996; Wiley; Volume: 26; Issue: 4 Linguagem: Sueco
10.1111/j.1365-2222.1996.tb00565.x
ISSN1365-2222
Tópico(s)Food Allergy and Anaphylaxis Research
ResumoClinical & Experimental AllergyVolume 26, Issue 4 p. 479-481 Free Access Review: P. S. FRIEDMANN, B. B. TAN, E. MUSABA & I. STRICKLAND First published: April 1996 https://doi.org/10.1111/j.1365-2222.1996.tb00565.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Bjorksten B, Kjellmann NIM. Perinatal factors influencing the development of allergy. Clin Rev Allergy 1987; 5: 339– 47. 2 Cookson WO, Sharp PA, Faux JA, Hopkin JM. Linkage between immunoglobulin E responses underlying asthma and rhinitis and chromosome llq. Lancet 1989; i: 1292– 5. 3 Young RP, Sharp PA, Lynch JR et al. Confirmation of genetic linkage between atopic IgE responses and chromosome 11q13. J Med Genet 1992; 29: 236– 8. 4 Coleman R, Trembath RC, Harper JI. Chromosome 1 Iq13 and atopy underlying atopic eczema. Lancet 1993; 341: 1121– 2. 5 Salvaggio JE, Cavanagh JJA, Lowell FC, Leskowitz S. A comparison of the immunologic responses of normal and atopic individuals to intranasally administered antigen. J Allergy 1964; 35: 62– 9. 6 Pene JF, Rousset F, Briere F et al. IgE production by normal human B cells induced by alloreactive T cell clones is mediated by IL-4 and suppressed by IFN-γ. J Immunol 1988; 141: 1218– 24. 7 Pene JF, Rousset F, Briere F, et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferon 7 and α and prostaglandin E2. Proc NatI Acad Sci USA 1988; 85: 6880– 6884. 8 Wierenga EA, Snoek M, De Groot C et al. Evidence for compartmentalization of functional subsets of CD2+ T lymphocytes in atopic patients. J Immunol 1990; 144: 4651– 6. 9 Parronchi P, Macchia D, Piccinni MP, et al. Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a diiferent profile of cytokine production. Proc NatI Acad Sci USA 1991; 88: 4538– 42. 10 Wierenga EA, Snoek M, Bos JD, Jansen HM, Kapsenberg ML. Comparison of diversity and function of house dust mite-specific T lymphocyte clones from atopic and nonatopic donors. Eur J Immunol 1990; 20: 1519– 26. 11 Reinhold U, Wehrmann W, Kukel S, Kreysel HW. Evidence that defective interferon-gamma production in atopic dermatitis patients is due to intrinsic abnormalities. Clin Exp Immunol 1990; 79: 374– 9. 12 Renz H, Jujo K, Bradley KL, Domenico J, Gelfand EW, Leung DY. Enhanced IL-4 production and IL-4 receptor expression in atopic dermatitis and their modulation by interferon-gamma. J Invest Dermatol 1992; 99: 403– 8. 13 Jujo K, Renz H, Abe J, Gelfand EW, Leung DY. Decreased interferon gamma and increased interleukin-4 production in atopic dermatitis promotes IgE synthesis. J Allergy Clin Immunol 1992; 90: 323– 31. 14 Rousset F, Robert J, Andary M, et al. Shifts in interleukin-4 and interferon-gamma production by T cells of patients with elevated serum IgE levels and the modulatory effects of these lymphokines on spontaneous IgE synthesis. J Allergy Clin Immunol 1991; 87: 58– 69. 15 Chan SC, Kim J-W, Henderson WR, Hanifin JR. Altered prostaglandin E2 regulation of cytokine production in atopic dermatitis. J Immunol 1993; 151: 3345– 52. 16 Tang MLK, Kemp AS, Thorburn J, Hill DJ. Reduced interferon-γ secretion in neonates and subsequent atopy. Lancet 1994; 344: 983– 5. 17 Warner JA, Miles EA, Jones AC et al. Is deficiency of of interferon gamma production by allergen triggered cord blood cells a predictor of atopic eczema? Clin Exp Allergy 1994; 24: 423– 30. 18 Rinas U, Horneff G, Wahn V. Interferon-gamma production by cord-blood mononuclear cells is reduced in newborns with a family history of atopic disease and is independent from cord blood IgE-levels. Pediatr Allergy Immunol 1993; 4: 60– 4. 19 Hoiden CA. Atopic dermatitis-messengers, second messengers and cytokines. Clin Exp Dermatol 1993; 18: 201– 7. 20 Parker CW, Kennedy S, Eisen AZ. Leukocyte and lymphocyte cyclic AMP responses in atopic eczema. J Invest Dermatol 1977; 68: 302– 7. 21 Betz M, Fox BS. Prostaglandin E2 inhibits production of Thl lymphokines but not of Th2 lymphokines. J Immunol 1991; 146: 108– 13. 22 Chan SC, Li SH, Hanifin JM. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phospho-diesterase activity and is reversible by phosphodiesterase inhibition. J Invest Dermatol 1993; 100: 681– 4. 23 Bruijnzeel Koomen CA, Van Wichen DF, Toonstra J, Berrens L, Bruijnzeel PL. The presence of IgE molecules on epidermal Langerhans cells in patients with atopic dermatitis. Arch Dermatol Res 1986; 278: 199– 205. 24 Mudde GC, Van Reijsen FC, Boland GJ, De Gast GC, Bruijnzeel PL, Bruijnzeel Koomen CA. Allergen presentation by epidermal Langerhans' cells from patients with atopic dermatitis is mediated by IgE. Immunology 1990; 69: 335– 41. 25 Bieber T, de la Salle H, Wollenberg A et al. Human epidermal Langerhans cells express the high affinity receptor for immunoglobuiin E (FcεRI). J Exp Med 1992; 175: 1285– 90. 26 Rieger A, Wang B, Kilgus O et al. Fc epsilon RI mediates IgE binding to human epidermal Langerhans cells. J Invest Dermatol 1992; 99: 30S– 32S. 27 Wang B, Rieger A, Kilgus O, et al. Epidermal Langerhans cells from normal human skin bind monomeric IgE via FceRI. J Exp Med 1992; 175: 1353– 65. 28 Bieber T. IgE-binding molecules on human Langerhans cells. Acta Derm Venereoi Suppl Stockh 1992; 176: 54– 7. 29 Van der Heijden FL, Joost van Neerven RJ, Van Katwijk M, Bos JD, Kapsenberg ML. Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol 1993; 150: 3643– 50. 30 Hauser C, Snapper CM, Ohara J, Paul WE, Katz SI. T helper cells grown with hapten-modified cultured Langerhans' cells produce interleukin 4 and stimulate IgE production by B cells. Eur J Immunol 1989; 19: 245– 51. 31 Munro CS, Higgins EM, Marks JM, Daly BM, Friedmann PS, Shuster S. Cyciosporin A in atopic dermatitis: therapeutic response is dissociated from effects on allergic reactions. Brit J Dermatol 1991; 124: 43– 8. 32 Ramb Lindhauer C, Feldmann A, Rotte M, Neumann C. Characterization of grass pollen reactive T-cell lines derived from lesional atopic skin. Arch Dermatol Res 1991; 283: 71– 6. 33 Rasanen L, Reunala T, Lehto M, Virtanen E, Arvilommi H. Immediate and delayed hypersensitivity reactions to birch pollen in patients with atopic dermatitis. Acta Derm Venereoi Stockh 1992; 72: 193– 6. 34 Bos JD, Kapsenberg ML, Smitt JH. Pathogenesis of atopic eczema. Lancet 1994; 343: 1338– 41. 35 Van Voorst Vader PC, Lier JG, Woest TE, Coenraads PJ, Nater JP. Patch tests with house dust mite antigens in atopic dermatitis patients: methodological problems. Acta Derm Venereoi Stockh 1991; 71: 301– 5. 36 Seidenari S, Manzini BM, Danese P, Giannetti A. Positive patch tests to whole mite culture and purified mite extracts in patients with atopic dermatitis, asthma, and rhinitis. Ann Allergy 1992; 69: 201– 6. 37 Bruijnzeel PL, Kuijper PH, Kapp A, Warringa RA, Betz S, Bruijnzeel Koomen CA. The involvement of eosinophils in the, patch test reaction to aeroallergens in atopic dermatitis: its relevance for the pathogenesis of atopic dermatitis. Clin Exp Allergy 1993; 23: 97– 109. 38 Wananukul S, Huiprasert P, Pongprasit P. Eczematous skin reaction from patch testing with aeroallergens in atopic children with and without atopic dermatitis. Pediatr Dermatol 1993; 10: 209– 13. 39 Tanaka M, Aiba S, Matsumura N, et al. IgE-mediated hypersensitivity and contact sensitivity to multiple envion-mental allergens in atopic dermatitis. Arch Dermatol 1994; 130: 1393– 401. 40 Cooper KD. Atopic dermatitis: recent trends in pathogenesis and therapy. J Invest Dermatol 1994; 102: 128– 37. 41 Van Reijsen FC, Bruijnzeel Koomen CA, Kalthoff FS, et al. Skin-derived aeroallergen-specific T-cell clones of Th2 phe-notype in patients with atopic dermatitis. J Allergy Clin Immunol 1992; 90: 184– 93. 42 Van der Heijden FL, Wierenga EA, Bos JD, Kapsenberg ML. High frequency of IL-4-producing CD4+ allergenspecific T lymphocytes in atopic dermatitis lesional skin. J Invest Dermatol 1991; 97: 389– 94. 43 Bos JD, Wierenga EA, Sillevis Smitt JH, Van der Heijden FL, Kapsenberg ML. Immune dysreguiation in atopic eczema. Arch Dermatol 1992; 128: 1509– 12. 44 Kay AB, Ying S, Varney V, et al. Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 1991; 173: 775– 8. 45 Grewe M, Gyufko K, Schopf E, Krutmann J. Lesional expression of interferon-gamma in atopic eczema. Lancet 1994; 343: 25– 6. 46 Hamid Q, Boguniewicz M, Leung DYM. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994; 94: 870– 6. 47 Clark RA, Adinoff AD. Aeroallergen contact can exacerbate atopic dermatitis: patch tests as a diagnostic tool. J Am Acad Dermatol 1989; 21: 863– 9. 48 Clark RA, Adinoff AD. The relationship between positive aeroallergen patch test reactions and aeroallergen exacerbations of atopic dermatitis. Clin Immunol Immunopathol 1989; 53: S132– S140. 49 Schopf E, Baumgartner A. Patch testing in atopic dermatitis. J Am Acad Dermatol 1989; 21: 860– 2. 50 Burton JL. Dietary fatty acids and infiammatory skin disease. Lancet 1989; i: 27– 31. 51 Morse PF, Horrobin DF, Manku MS, et al. Meta-analysis of placebo-controlled studies of the efficacy of Epogam in the treatment of atopic exzema. Relationship between plasma essential fatty acid changes and clinical response. Brit J Dermatol 1989; 121: 75– 90. 52 Bamford JTM, Gibson RW, Renier CM. Atopic eczema unresponsive to evening primrose oil (linoleic and γ-linolenic acids). J Am Acad Dermatol 1985; 13: 959– 65. 53 Berth-Jones J, Graham-Brown RAC. Placebo-controlled trial of essential fatty acid supplementation in atopic dermatitis. Lancet 1993; 341: 1557– 60. 54 Cowley NC, Farr PM. A dose-response study of irritant reactions to sodium lauryl sulphate in patients with seborrhoeic dermatitis and atopic eczema. Acta Derm Venereoi Stockh 1992; 72: 432– 5. 55 Logan RA, Camp RDR. Severe atopic eczema: response to oral cyciosporin A. J Roy Soc Med 1988; 81: 417– 8. 56 Motley RJ, Whittaker JA, Holt PJA. Resolution of atopic dermatitis in a patient treated with cyciosporin. Clin Exp Dermatol 1989; 14: 243– 4. 57 Van Joost T, Kozel MM, Tank B, Troost R, Prens EP. Cyclosporine in atopic dermatitis. Modulation in the expression of immunologic markers in lesional skin. J Am Acad Dermatol 1992; 27: 922– 8. 58 Higgins EM, McLelland J, Friedmann PS, Matthews JNS, Shuster S. Oral Cyciosporin A inhibits the expression of contact hypersensitivity in man. J Dermatol Sci 1991; 2: 79– 83. 59 Cooper KD, Baadsgaard O, Ellis CN, Duell E, Voorhees JJ. Mechanisms of cyclosporine A inhibition of antigen-presenting activity in uninvolved and lesional psoriatic epidermis. J Invest Dermatol 1990; 94: 649– 56. 60 Munro CS, Levell NJ, Shuster S, Friedmann PS. Maintenance treatment with Cyciosporin in atopic eczema. Brit J Dermatol 1994; 130: 376– 80. 61 Sepp N, Fritsch PO. Can Cyciosporin A induce permanent remission of atopic dermatitis? Brit J Dermatol 1993; 128: 213– 6. 62 Krutmann J, Czech W, Diepgen T, Niedner R, Kapp A, Schopf E. High-dose UVAI therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 1992; 26: 225– 30. 63 Minaguchi S, Yoshiike T, Aikawa Y, Nakajima S, Sindhvananda J, Ogawa H. [Topical psoralen photochemotherapy (PUVA therapy) for severe atopic dermatitis (I): An analysis of correlation between effectiveness of PUVA therapy and chnical parameters]. Nippon Hifuka Gakkai Zasshi 1990; 100: 1251– 5. 64 Sheehan MP, Atherton DJ, Norris P, Hawk J. Oral psoralen photochemotherapy in severe childhood atopic eczema: an update. Brit J Dermatol 1993; 129: 431– 6. 65 Friedmann PS, Ford GP, Ross J, Diffey BL. Reappearance of Epidermal Langerhans cells after PUVA therapy. Brit J Dermatol 1983; 109: 301– 8. 66 Gruner S, Hofmann T, Meffert H, Sonnichsen N. Studies on the effects of a high dose UVA-1 radiation therapy on surface markers and function of epidermal Langerhans cells. Arch Dermatol Res 1993; 285: 283– 6. 67 Soderberg U, Windelborg Nielsen B, Schade Larsen C, Schiotz PO, Thestrup Pedersen K. Time-course studies of immediate and delayed immune reactivity in patients with atopic dermatitis treated with herbal drugs. Allergy 1990; 45: 559– 65. 68 Sheehan MP, Rustin MH, Atherton DJ, et al. Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet 1992; 340: 13– 7. 69 Sheehan MP, Atherton DJ. A controlled trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema. Brit J Dermatol 1992; 126: 179– 84. 70 Wessels MW, Doekes G, Van Ieperen Van Kijk AG, Koers WJ, Young E. IgE antibodies to Pityrosporum ovale in atopic dermatitis. Brit J Dermatol 1991; 125: 227– 32. 71 Souillet G, Rousset F, De Vries JE. Alpha-interferon treatment of patient with hyper IgE syndrome. Lancet 1989; i: 1384. 72 Nielsen BW, Reimert CM, Hammer R, Schiotz PO, Thestrup Pedersen K. Interferon therapy for atopic dermatitis reduces basophil histamine release, but does not reduce serum IgE or eosinophilic proteins. Allergy 1994; 49: 120– 8. 73 Gruschwitz MS, Peters KP, Heese A, Stosiek N, Koch HU, Hornstein OP. Effects of interferon-alpha-2b on the clinical course, inflammatory skin infiltrates and peripheral blood lymphocytes in patients with severe atopic eczema. Int Arch Allergy Immunol 1993; 101: 20– 30. 74 Torrelo A, Harto A, Sendagorta E, Czarnetzki BM, Ledo A. Interferon-alpha therapy in atopic dermatitis. Acta Derm Venereoi Stockh 1992; 72: 370– 2. 75 Reinhold U, Kukel S, Brzoska J, Kreysel HW. Systemic interferon gamma treatment in severe atopic dermatitis. J Am Acad Dermatol 1993; 29: 58– 63. 76 Hanifin JM, Schneider LC, Leung DY et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993; 28: 189– 97. 77 Hsieh KH, Shaio MF, Liao TN. Thymopentin treatment in severe atopic dermatitis-clinical and immunological evaluations. Arch Dis Child 1992; 67: 1095– 102. 78 Roberts DLL. House dust mite avoidance and atopic dermatitis. Brit J Dermatol 1984; 110: 735– 6. 79 August PJ. House dust mite causes atopic eczema. A preliminary study. Brit J Dermatol 1984; 111, Suppl 26: 10– 1. 80 Denman AM, Cornthwaite D. Control of house dust mite in bedding. Lancet 1990; 335: 1038. 81 Warner JA, Marchant JL, Warner JO. Allergen avoidance in the homes of asthmatic children:the effect of Ailersearch DMS. Clin Exp Allergy 1993; 23: 279– 86. 82 Marks GB, Tovey ER, Green W, Shearer M, Salome CM, Woolcock AJ. House dust mite allergen avoidance:a randomised controlled trial of surface chemical treatment and encasement of bedding. Clin Exp Allergy 1994; 24: 1078– 83. 83 Van Bever HP, Docx M, Stevens WJ. Food and food additives in severe atopic dermatitis. Allergy 1989; 44: 588– 94. 84 Goldenhersh MA. Atopic dermatitis and food hypersensitivity [letter]. N Engl J Med 1990; 322: 274– 5. 85 Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113 patients. J Paediatr 1985; 107: 669– 75. Volume26, Issue4April 1996Pages 479-481 ReferencesRelatedInformation
Referência(s)